Patents by Inventor Girish Chopda

Girish Chopda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting HMGB1 expression
    Patent number: 11478501
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 25, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
    Publication number: 20220072024
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be either double-stranded or single-stranded and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Inventors: Marc ABRAMS, Girish CHOPDA, Uihye PARK
  • COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
    Publication number: 20200297754
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Application
    Filed: April 30, 2020
    Publication date: September 24, 2020
    Inventors: Marc ABRAMS, Girish CHOPDA, Jihye PARK
  • Compositions and methods for inhibiting HMGB1 expression
    Patent number: 10675295
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
    Publication number: 20190000870
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 3, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park